Refine by
Industries served
- Medical / Health Care
- Monitoring and Testing
- Chemical & Pharmaceuticals
- Manufacturing, Other
- Agriculture
- University / Academia / Research
- Mining
- Banking & Finance / Insurance / Legal
- Electronics and Computers
- Glassware
- Oil, Gas & Refineries
- Water and Wastewater
- Environmental
- Health and Safety
- Air and Climate
- Government
- Energy
Cancer Cell Suppliers & Manufacturers
257 companies found
based inCambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...
We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody ...
based inBasel, SWITZERLAND
We at Auris Medical are a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. We are focusing on the development of intranasal betahistine ...
The OligoPhore™ / SemaPhore™ technology has been extensively and successfully tested with various siRNA and mRNA sequences in numerous disease models in mice. For the development of our first proprietary drug product, AM-401 ...
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
based inChuo-ku, JAPAN
Sysmex has a global network of operations throughout the world. This section introduces our company profile and provides the locations of our offices and subsidiaries. Sysmex supports human health. We are an integrated company, developing and ...
Also, it takes more than one hour for the gene amplification reaction. Sysmex has developed the one-step measurement technology for cancer cell derived biomarkers (CK19mRNA) in the lymph node by optimizing ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Bispecific T cell engaging receptors (TCER®) are off-the-shelf biologics that leverage the body’s immune system by redirecting and activating T cells towards cancer cells ...
based inShirley, NEW YORK (USA)
Creative Bioarray is a leading customer-centered biotechnology company and a pioneer with the latest technology of cell patterning. Creative Bioarray has an experienced expert team and is committed to providing comprehensive services and customized ...
Compared with normal cells, tumor cells have undergone a series of genetic and epigenetic alterations that, in general, underlie cancer development, progression, and drug resistance. Tumor-derived ...
based inYokohama, JAPAN
MabGenesis Inc. is a biopharmaceutical startup that uses 30+ years of antibody research to provide first-in-class and best-in-class therapeutic monoclonal antibody drugs for humans and animals. We have the world’s highest quality antibody libraries ...
Technology and knowledge on variable region amplification and optimal combinations of heavy and light chains: A high-quality library (MOURA library) consisting of 1011 diverse and functional clones, constructed by original gene amplification ...
based inCarlsbad, CALIFORNIA (USA)
Our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage’s programs are based on the Company’s proprietary cell-based therapy platform and associated ...
VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in ...
based inBarcelona, SPAIN
INTERmedic is a dynamic company that is still expanding, after more than 25 years in the medical technology business sector. INTERmedic develops, manufactures and distributes innovative medical systems, based on the most advanced laser technology ...
based inWellesley Hills, MASSACHUSETTS (USA)
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 50 countries, TargetMol has evolved into one of ...
based inDanvers, MASSACHUSETTS (USA)
Neutron Therapeutics is a medical equipment company founded in November 2015. We are working to bring Boron Neutron Capture Therapy (BNCT) out of the realm of medical research and transform it into a widely available first-line cancer therapy. We ...
A Promising Non-Invasive Therapy for Cancer Patients; Boron Neutron Capture Therapy (BNCT) is a unique type of radiation therapy that enables targeting of cancer at the cellular level. BNCT has been used to treat cancer with a non-invasive two-step ...
based inBaton Rouge, LOUISIANA (USA)
Oleander Medical Technologies is developing a revolutionary new treatment to destroy many of the most invasive and deadly cancers using a process called Targeted Osmotic Lysis ...
Targeted Osmotic Lysis (TOL) is a revolutionary treatment for advanced cancer, combining a generic drug (a cardiac glycoside) with a proprietary pulsed electric field ...
based inxiamen, CHINA
XIAMEN SPACEGEN Co., Ltd. is a high-tech molecular diagnostic biology enterprise integrating R&D, production, sales and service. The company leads technological innovation guided by clinical needs ,providing high-quality and accessible molecular ...
Detection Gene:K-ras (covering 21 loci related to targeted drugs). Detection Significance:Guiding the selection of KRAS G12C inhibitor , anti-EGFR and ...
based inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
based inNew York, NEW YORK (USA)
We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we seek to capitalize on ...
Our licensed gene therapy, CO-sTiRNA™, is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA™ is a highly selective and targeted gene therapy that ...
based inDidcot, UNITED KINGDOM
We design, develop and manufacture nanofibrous biomaterials for medical devices and regenerative medicine. Our technology platform is built on electrospinning and associated processing technologies. We are supporting clients with material ...
The thickness of Mimetix scaffold allows for having a 3D environment while maintaining a certain translucence, thus allowing for easy and robust imaging. This study has investigated the localisation depth of MCF7 breast cancer ...
based inFlagstaff, ARIZONA (USA)
Symple Surgical is an exciting start-up Medical Device company focused on developing novel therapeutic technologies through controlled Microwave Ablation. Our technologies are thoughtfully designed to be familiar and easy to use by the operator ...
based inXiamen, CHINA
Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based diagnostic company, focusing on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS®, Super-ARMS®, ddCapture® and ADx-HANDLE® ...
Lung cancer is one of the most common malignant tumor, and 80~85% of lung cancers are non-small cell lung cancer (NSCLC). There are many driver mutations in NSCLC. The frequency of ...
based inHouston, TEXAS (USA)
CUSABIO is a National High-Tech Enterprise with research, production and sales in one. After 16 years of effort, CUSABIO has become a good partner to researchers through worldwide. We are dedicated to providing 60,000+ validated antibodies, 10,000+ ...
based inPrinceton, NEW JERSEY (USA)
Taiho Oncology, Inc. specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a ...
Tumors with specific FGFR aberrations: Solid tumors, Gastric cancer, Myelolymphoid neoplasms PHASE ...
